Koninklijke Philips N.V.
Koninklijke Philips N.V. (PHIA.AS) Stock Competitors & Peer Comparison
See (PHIA.AS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHIA.AS | €23.58 | -0.08% | 22.4B | 25.35 | €0.93 | +3.60% |
| IBAB.BR | €12.64 | -3.51% | 370.4M | 29.40 | €0.43 | +1.90% |
| ALERS.PA | €22.50 | +5.88% | 226.5M | 102.27 | €0.22 | N/A |
| ALMDT.PA | €4.55 | -2.05% | 171.1M | -3.92 | -€1.16 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| EAPI.PA | €1.26 | -3.08% | 120.4M | -0.97 | -€1.31 | N/A |
| GBT.PA | €9.08 | -2.37% | 114.4M | -1.02 | -€8.91 | N/A |
| AFME.PA | €2.81 | +0.00% | 110.4M | -7.81 | -€0.36 | N/A |
| SEQUA.BR | €0.50 | -4.40% | 38.8M | -0.41 | -€1.23 | N/A |
| ALIMP.PA | €0.22 | -1.35% | 31.5M | -7.30 | -€0.03 | N/A |
Stock Comparison
PHIA.AS vs IBAB.BR Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, IBAB.BR has a market cap of 370.4M. Regarding current trading prices, PHIA.AS is priced at €23.58, while IBAB.BR trades at €12.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas IBAB.BR's P/E ratio is 29.40. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to IBAB.BR's ROE of +0.10%. Regarding short-term risk, PHIA.AS is more volatile compared to IBAB.BR. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check IBAB.BR's competition here
PHIA.AS vs ALERS.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALERS.PA has a market cap of 226.5M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALERS.PA trades at €22.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALERS.PA's P/E ratio is 102.27. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALERS.PA's ROE of +0.01%. Regarding short-term risk, PHIA.AS is less volatile compared to ALERS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALERS.PA's competition here
PHIA.AS vs ALMDT.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALMDT.PA has a market cap of 171.1M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALMDT.PA trades at €4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALMDT.PA's P/E ratio is -3.92. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALMDT.PA's ROE of +0.59%. Regarding short-term risk, PHIA.AS is less volatile compared to ALMDT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALMDT.PA's competition here
PHIA.AS vs ALCOR.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, PHIA.AS is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALCOR.PA's competition here
PHIA.AS vs EAPI.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, EAPI.PA has a market cap of 120.4M. Regarding current trading prices, PHIA.AS is priced at €23.58, while EAPI.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas EAPI.PA's P/E ratio is -0.97. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to EAPI.PA's ROE of -0.24%. Regarding short-term risk, PHIA.AS is less volatile compared to EAPI.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check EAPI.PA's competition here
PHIA.AS vs GBT.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, GBT.PA has a market cap of 114.4M. Regarding current trading prices, PHIA.AS is priced at €23.58, while GBT.PA trades at €9.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas GBT.PA's P/E ratio is -1.02. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to GBT.PA's ROE of -0.34%. Regarding short-term risk, PHIA.AS is less volatile compared to GBT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check GBT.PA's competition here
PHIA.AS vs AFME.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, AFME.PA has a market cap of 110.4M. Regarding current trading prices, PHIA.AS is priced at €23.58, while AFME.PA trades at €2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas AFME.PA's P/E ratio is -7.81. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to AFME.PA's ROE of -0.57%. Regarding short-term risk, PHIA.AS is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check AFME.PA's competition here
PHIA.AS vs SEQUA.BR Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, SEQUA.BR has a market cap of 38.8M. Regarding current trading prices, PHIA.AS is priced at €23.58, while SEQUA.BR trades at €0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas SEQUA.BR's P/E ratio is -0.41. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to SEQUA.BR's ROE of +1.24%. Regarding short-term risk, PHIA.AS is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check SEQUA.BR's competition here
PHIA.AS vs ALIMP.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALIMP.PA has a market cap of 31.5M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALIMP.PA trades at €0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALIMP.PA's P/E ratio is -7.30. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALIMP.PA's ROE of +13.76%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALIMP.PA's competition here
PHIA.AS vs MKEA.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, PHIA.AS is priced at €23.58, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, PHIA.AS is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check MKEA.PA's competition here
PHIA.AS vs ALNOV.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALNOV.PA has a market cap of 27M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALNOV.PA trades at €0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALNOV.PA's P/E ratio is -0.79. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALNOV.PA's ROE of -0.15%. Regarding short-term risk, PHIA.AS is less volatile compared to ALNOV.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALNOV.PA's competition here
PHIA.AS vs ALDMS.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALDMS.PA has a market cap of 26.5M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALDMS.PA trades at €1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALDMS.PA's P/E ratio is -9.77. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALDMS.PA's ROE of -0.13%. Regarding short-term risk, PHIA.AS is more volatile compared to ALDMS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALDMS.PA's competition here
PHIA.AS vs ALIKO.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALIKO.PA has a market cap of 22.7M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALIKO.PA trades at €1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALIKO.PA's P/E ratio is -6.26. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, PHIA.AS is less volatile compared to ALIKO.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALIKO.PA's competition here
PHIA.AS vs ALTHE.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALTHE.PA has a market cap of 21.6M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALTHE.PA trades at €0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALTHE.PA's P/E ratio is -4.17. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALTHE.PA's ROE of +4.68%. Regarding short-term risk, PHIA.AS is less volatile compared to ALTHE.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALTHE.PA's competition here
PHIA.AS vs ALTER.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, PHIA.AS is less volatile compared to ALTER.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALTER.PA's competition here
PHIA.AS vs ALEMG.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALEMG.PA has a market cap of 12.3M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALEMG.PA trades at €4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALEMG.PA's P/E ratio is 11.39. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALEMG.PA's ROE of -0.33%. Regarding short-term risk, PHIA.AS is less volatile compared to ALEMG.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALEMG.PA's competition here
PHIA.AS vs ALBLU.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALBLU.PA has a market cap of 9M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALBLU.PA trades at €0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALBLU.PA's P/E ratio is -8.17. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALBLU.PA's ROE of -0.71%. Regarding short-term risk, PHIA.AS is more volatile compared to ALBLU.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check ALBLU.PA's competition here
PHIA.AS vs ALSGD.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALSGD.PA has a market cap of 7.3M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALSGD.PA trades at €0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALSGD.PA's P/E ratio is -2.94. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALSGD.PA's ROE of -0.63%. Regarding short-term risk, PHIA.AS is less volatile compared to ALSGD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALSGD.PA's competition here
PHIA.AS vs ALCAR.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, ALCAR.PA has a market cap of 6.4M. Regarding current trading prices, PHIA.AS is priced at €23.58, while ALCAR.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas ALCAR.PA's P/E ratio is -0.09. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to ALCAR.PA's ROE of +1.07%. Regarding short-term risk, PHIA.AS is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check ALCAR.PA's competition here
PHIA.AS vs VMGBS.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, VMGBS.PA has a market cap of 0. Regarding current trading prices, PHIA.AS is priced at €23.58, while VMGBS.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas VMGBS.PA's P/E ratio is N/A. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to VMGBS.PA's ROE of N/A. Regarding short-term risk, PHIA.AS is more volatile compared to VMGBS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for PHIA.AS.Check VMGBS.PA's competition here
PHIA.AS vs DGM.PA Comparison April 2026
PHIA.AS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHIA.AS stands at 22.4B. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, PHIA.AS is priced at €23.58, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHIA.AS currently has a P/E ratio of 25.35, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, PHIA.AS's ROE is +0.08%, compared to DGM.PA's ROE of -0.23%. Regarding short-term risk, PHIA.AS is less volatile compared to DGM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for PHIA.AS.Check DGM.PA's competition here